Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Ther Methods Clin Dev ; 29: 439-449, 2023 Jun 08.
Article in English | MEDLINE | ID: mdl-37251981

ABSTRACT

Mucopolysaccharidosis I (MPS I), a lysosomal storage disease caused by dysfunction of α-L-iduronidase (IDUA), is characterized by the deposition of dermatan sulfate (DS) and heparan sulfate (HS) throughout the body, which causes several somatic and central nervous symptoms. Although enzyme-replacement therapy (ERT) is currently available to treat MPS I, it does not alleviate central nervous disorders, as it cannot penetrate the blood-brain barrier. Here we evaluate the brain delivery, efficacy, and safety of JR-171, a fusion protein comprising humanized anti-human transferrin receptor antibody Fab and IDUA, using monkeys and MPS I mice. Intravenously administered JR-171 was distributed in major organs, including the brain, and reduced DS and HS concentrations in the central nervous system and peripheral tissues. JR-171 exerted similar effects on peripheral disorders similar to conventional ERT and further reversed brain pathology in MPS I mice. We found that JR-171 improved spatial learning ability, which was seen to deteriorate in the vehicle-treated mice. Further, no safety concerns were noted in repeat-dose toxicity studies in monkeys. This study provides nonclinical evidence that JR-171 might potentially prevent and even improve disease conditions in patients with neuronopathic MPS I without serious safety concerns.

2.
Mol Ther ; 29(5): 1853-1861, 2021 05 05.
Article in English | MEDLINE | ID: mdl-33508431

ABSTRACT

Mucopolysaccharidosis II (MPS II), a lysosomal storage disease caused by mutations in iduronate-2-sulfatase (IDS), is characterized by a wide variety of somatic and neurologic symptoms. The currently approved intravenous enzyme replacement therapy with recombinant IDS (idursulfase) is ineffective for CNS manifestations due to its inability to cross the blood-brain barrier (BBB). Here, we demonstrate that the clearance of heparan sulfate (HS) deposited in the brain by a BBB-penetrable antibody-enzyme fusion protein prevents neurodegeneration and neurocognitive dysfunctions in MPS II mice. The fusion protein pabinafusp alfa was chronically administered intravenously to MPS II mice. The drug reduced HS and attenuated histopathological changes in the brain, as well as in peripheral tissues. The loss of spatial learning abilities was completely suppressed by pabinafusp alfa, but not by idursulfase, indicating an association between HS deposition in the brain, neurodegeneration, and CNS manifestations in these mice. Furthermore, HS concentrations in the brain and reduction thereof by pabinafusp alpha correlated with those in the cerebrospinal fluid (CSF). Thus, repeated intravenous administration of pabinafusp alfa to MPS II mice decreased HS deposition in the brain, leading to prevention of neurodegeneration and maintenance of neurocognitive function, which may be predicted from HS concentrations in CSF.


Subject(s)
Brain/metabolism , Heparitin Sulfate/metabolism , Mucopolysaccharidosis II/drug therapy , Neurocognitive Disorders/prevention & control , Recombinant Fusion Proteins/administration & dosage , Recombinant Proteins/administration & dosage , Administration, Intravenous , Animals , Antibodies/genetics , Blood-Brain Barrier , Brain/drug effects , Disease Models, Animal , Glycoproteins/genetics , Heparitin Sulfate/cerebrospinal fluid , Humans , Iduronate Sulfatase/administration & dosage , Iduronate Sulfatase/pharmacology , Immunoglobulin G/chemistry , Immunoglobulin G/genetics , Mice , Mucopolysaccharidosis II/cerebrospinal fluid , Mucopolysaccharidosis II/psychology , Neurocognitive Disorders/etiology , Receptors, Transferrin/antagonists & inhibitors , Recombinant Fusion Proteins/pharmacology , Recombinant Proteins/genetics , Recombinant Proteins/pharmacology , Spatial Learning/drug effects
3.
Int J Mol Sci ; 20(23)2019 Nov 20.
Article in English | MEDLINE | ID: mdl-31757021

ABSTRACT

Mucopolysaccharidosis type II (MPS II) is a rare lysosomal storage disease (LSD) involving a genetic error in iduronic acid-2-sulfatase (IDS) metabolism that leads to accumulation of glycosaminoglycans within intracellular lysosomes. The primary treatment for MPS II, enzyme replacement therapy, is not effective for central nervous system (CNS) symptoms, such as intellectual disability, because the drugs do not cross the blood-brain barrier. Recently, autophagy has been associated with LSDs. In this study, we examined the morphologic relationship between neuronal damage and autophagy in IDS knockout mice using antibodies against subunit c of mitochondrial adenosine triphosphate (ATP) synthetase and p62. Immunohistological changes suggesting autophagy, such as vacuolation, were observed in neurons, microglia, and pericytes throughout the CNS, and the numbers increased over postnatal development. Oral administration of chloroquine, which inhibits autophagy, did not suppress damage to microglia and pericytes, but greatly reduced neuronal vacuolation and eliminated neuronal cells with abnormal inclusions. Thus, decreasing autophagy appears to prevent neuronal degeneration. These results suggest that an autophagy modulator could be used in addition to conventional enzyme replacement therapy to preserve the CNS in patients with MPS II.


Subject(s)
Autophagy , Mucopolysaccharidosis II/metabolism , Neurons/metabolism , Animals , Brain/metabolism , Brain/pathology , Chloroquine/pharmacology , Iduronate Sulfatase/genetics , Male , Mice , Mice, Inbred C57BL , Microglia/drug effects , Microglia/metabolism , Microglia/ultrastructure , Mitochondrial Proton-Translocating ATPases/genetics , Mitochondrial Proton-Translocating ATPases/metabolism , Mucopolysaccharidosis II/pathology , Neurons/drug effects , Neurons/ultrastructure , Sequestosome-1 Protein/genetics , Sequestosome-1 Protein/metabolism
4.
Mol Genet Metab ; 125(1-2): 53-58, 2018 09.
Article in English | MEDLINE | ID: mdl-30064964

ABSTRACT

Mucopolysaccharidosis type II (MPS II or Hunter syndrome) is a lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase (IDS), an enzyme that catabolizes glycosaminoglycans (GAGs) including heparan sulfate (HS) and dermatan sulfate (DS). GAG accumulation leads to severe neurological and somatic impairments. At present, the most common treatment for MPS II is intravenous enzyme replacement therapy; however, the inability of recombinant IDS to cross the blood-brain barrier (BBB) restricts therapeutic efficacy for neurological manifestations. We recently developed a BBB-penetrating IDS fusion protein, JR-141, and demonstrated its ability to reduce GAG accumulation in the brain of human transferrin receptor knock-in and Ids knock-out mice (TFRC-KI/Ids-KO), an animal model of MPS II, following intravenous administration. Given the impossibility of measuring GAG accumulation in the brains of human patients with MPS II, we hypothesized that GAG content in the cerebrospinal fluid (CSF) might serve as an indicator of brain GAG burden. To test this hypothesis, we optimized a high-sensitivity method for quantifying HS and DS in low-volume samples by combining acidic methanolysis and liquid chromatography-tandem mass spectrometry (LC/MS/MS). We employed this method to quantify HS and DS in samples from TFRC-KI/Ids-KO mice and revealed that HS but not DS accumulated in the central nerve system (CNS). Moreover, concentrations of HS in CSF correlated with those in brain. Finally, intravenous treatment with JR-141 reduced levels of HS in the CSF and brain in TFRC-KI/Ids-KO mice. These results suggest that CSF HS content may be a useful biomarker for evaluating the brain GAG accumulation and the therapeutic efficacy of drugs in patients with MPS II.


Subject(s)
Biomarkers/cerebrospinal fluid , Heparitin Sulfate/cerebrospinal fluid , Mucopolysaccharidosis II/cerebrospinal fluid , Nervous System Diseases/cerebrospinal fluid , Animals , Blood-Brain Barrier/drug effects , Brain/drug effects , Brain/metabolism , Brain/pathology , Chromatography, Liquid , Dermatan Sulfate/cerebrospinal fluid , Disease Models, Animal , Heparitin Sulfate/genetics , Humans , Iduronate Sulfatase/genetics , Mice , Mice, Knockout , Mucopolysaccharidosis II/drug therapy , Mucopolysaccharidosis II/genetics , Mucopolysaccharidosis II/pathology , Nervous System Diseases/pathology , Receptors, Transferrin/genetics , Tandem Mass Spectrometry
5.
Am J Physiol Gastrointest Liver Physiol ; 311(5): G859-G868, 2016 11 01.
Article in English | MEDLINE | ID: mdl-27659420

ABSTRACT

Glycosylation is involved in various pathophysiological conditions. N-Acetylglucosaminyltransferase V (GnT-V), catalyzing ß1-6 branching in asparagine-linked oligosaccharides, is one of the most important glycosyltransferases involved in cancer and the immune system. Recent findings indicate that aberrant N-glycan structure can modify lipid metabolism. In this study, we investigated the effects of aberrant glycosylation by GnT-V on high-density lipoprotein cholesterol (HDL) assembly. We used GnT-V transgenic (Tg) mice and GnT-V Hep3B cell (human hepatoma cell line) transfectants. The study also included 96 patients who underwent medical health check-ups. Total serum cholesterol levels, particularly HDL-cholesterol (HDL-C) levels, were significantly increased in Tg vs. wild-type (WT) mice. Hepatic expression of apolipoprotein AI (ApoAI) and ATP-binding cassette subfamily A member 1 (ABCA1), two important factors in HDL assembly, were higher in Tg mice compared with WT mice. ApoAI and ABCA1 were also significantly elevated in GnT-V transfectants compared with mock-transfected cells. Moreover, ApoAI protein in the cultured media of GnT-V transfectants was significantly increased. Finally, we found a strong correlation between serum GnT-V activity and HDL-C concentration in human subjects. Multivariate logistic analyses demonstrated that GnT-V activity was an independent and significant determinant for serum HDL-C levels even adjusted with age and gender differences. Further analyses represented that serum GnT-V activity had strong correlation especially with the large-size HDL particle concentration. These findings indicate that enhanced hepatic GnT-V activity accelerated HDL assembly and could be a novel mechanism for HDL synthesis.


Subject(s)
Lipoproteins, HDL/metabolism , Liver/metabolism , N-Acetylglucosaminyltransferases/metabolism , ATP Binding Cassette Transporter 1/metabolism , Animals , Apolipoproteins A/metabolism , Cell Line, Tumor , Female , Glycosylation , Humans , Male , Mice , Mice, Transgenic , Middle Aged , Phosphorylation
6.
Hepatol Res ; 46(3): E118-29, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26041473

ABSTRACT

AIM: Glycosylation changes induce various types of biological phenomena in human diseases. N-Acetylglucosaminyltransferase V (GnT-V) is one of the most important glycosyltransferases involved in cancer biology. Recently, many researchers have challenged studies of lipid metabolism in cancer. To elucidate the relationships between cancer and lipid metabolism more precisely, we investigated the effects of GnT-V on lipid metabolism. In this study, we investigated the effects of aberrant glycosylation by GnT-V on hepatic triglyceride production. METHODS: We compared lipid metabolism in GnT-V transgenic (Tg) mice with that of wild-type (WT) mice fed with normal chow or a choline-deficient amino acid-defined (CDAA) diet in vivo. HepG2 cells and GnT-V transfectants of Hep3B cells were used in an in vitro study. RESULTS: Serum triglyceride levels and hepatic very low-density lipoprotein (VLDL) secretion in Tg mice were significantly elevated compared with that of WT mice. Hepatic lipogenic genes (Lxrα, Srebp1, Fas and Acc) and VLDL secretion-related gene (Mttp1) were significantly higher in Tg mice. Expression of these genes was also significantly higher in GnT-V transfectants than in mock cells. Knockdown of GnT-V decreased, while both epidermal growth factor and transforming growth factor-ß1 stimulation increased LXRα gene expression in HepG2 cells. Finally, we found that the blockade of VLDL secretion by CDAA diet induced massive hepatic steatosis in Tg mice. CONCLUSION: Our study demonstrates that enhancement of hepatic GnT-V activity accelerates triglyceride synthesis and VLDL secretion. Glycosylation modification by GnT-V regulation could be a novel target for a therapeutic approach to lipid metabolism.

7.
Liver Int ; 35(3): 925-35, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25627311

ABSTRACT

BACKGROUND & AIMS: Fetuin-A (α2HS-glycoprotein), a liver secretory glycoprotein, is known as a transforming growth factor (TGF)-ß1 signalling inhibitor. Serum fetuin-A concentration is associated with nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. However, the usefulness of serum fetuin-A as a predictive fibrosis biomarker in NAFLD patients remains unclear. In this study, we investigated the relationship between circulating fetuin-A levels and fibrosis-related markers [platelet count, NAFLD fibrosis score and carotid intima media thickness (IMT)] in subjects with NAFLD. METHODS: A total of 295 subjects (male, 164; female, 131) who received medical health check-ups were enrolled in this study. NAFLD was diagnosed using abdominal ultrasonography. Serum fetuin-A was measured by ELISA. IMT was assessed using a high-resolution ultrasound scanner. Using recombinant human fetuin-A, we investigated the effects of fetuin-A on hepatic stellate cells, which play a pivotal role in the process of hepatic fibrosis. RESULTS: Serum fetuin-A concentration was significantly correlated with platelet count (R = 0.19, P < 0.01), NAFLD fibrosis score (R = -0.25, P < 0.01) and mean IMT (R = -0.22, P < 0.01). Multivariate analyses revealed that the fetuin-A concentration is a significant and independent determinant of platelet count, NAFLD fibrosis score and mean IMT. Recombinant fetuin-A suppressed TGF-ß1 signalling and fibrosis-related gene expression and increased the expression of TGF-ß1 pseudoreceptor bone morphogenic protein and activin membrane-bound inhibitor (BAMBI). CONCLUSIONS: Serum fetuin-A level is associated with liver/vessel fibrosis-related markers in NAFLD patients. Circulating fetuin-A could be a useful serum biomarker for predicting liver and vascular fibrosis progression in NAFLD patients.


Subject(s)
Liver/pathology , Non-alcoholic Fatty Liver Disease/blood , alpha-2-HS-Glycoprotein/metabolism , Aged , Biomarkers/blood , Carotid Intima-Media Thickness , Cell Line , Female , Fibrosis , Hepatic Stellate Cells/metabolism , Humans , Male , Middle Aged , Non-alcoholic Fatty Liver Disease/pathology , Platelet Count , Transforming Growth Factor beta1
8.
Mol Med Rep ; 11(5): 3573-84, 2015 May.
Article in English | MEDLINE | ID: mdl-25572342

ABSTRACT

N­Acetylglucosaminyltransferase V (GnT­V) catalyzes ß1­6 branching in asparagine­linked oligosaccharides and is one of the most important glycosyltransferases involved in carcinogenesis, cancer metastasis and immunity. To investigate the biological functions of GnT­V, the present study developed GnT­V transgenic (Tg) mice and the role of GnT­V in experimental immune­mediated hepatitis, induced by concanavalin A (ConA), were investigated. It was found that the aberrant expression of GnT­V exacerbated ConA­induced hepatitis in the Tg mice compared with the wild­type (WT) mice. The survival rate of the ConA­induced hepatitis at a high­dose of ConA was significantly lower in the Tg mice. Intravenously injected ConA is known to initially bind predominantly to the mannose gland of the liver sinusoidal endothelial cell (LSEC) surface and to leads to the activation of various immune cells. In the present study, the binding affinity of ConA to the LSECs did not differ between the WT and Tg mice. In addition, T cell receptor stimulation by anti­cluster of differentiation (CD)3/CD28 antibodies produced lower levels of T helper (Th)1 cytokine (interferon­Î³) and higher levels of Th2 cytokine (interleukin­10) in the Tg mouse splenic lymphocytes compared with WT mice. The composition of the hepatic mononuclear cells revealed that CD11b­positive cells were significantly increased in the GnT­V Tg mice. In addition, F4/80­positive cells were significantly increased in the Tg mouse liver and the depletion of macrophages reduced the difference in the severity of ConA­induced hepatitis between the WT and Tg mice. In conclusion, the present findings indicated that the aberrant expression of GnT­V led to an increase in hepatic macrophage infiltration and enhanced ConA­induced hepatitis. Modulation of glycosylation may be a novel therapeutic target for immunity­associated acute hepatitis.


Subject(s)
Chemical and Drug Induced Liver Injury/genetics , Chemical and Drug Induced Liver Injury/pathology , N-Acetylglucosaminyltransferases/genetics , Animals , Cell Count , Chemical and Drug Induced Liver Injury/immunology , Concanavalin A/adverse effects , Cytokines/metabolism , Disease Models, Animal , Disease Progression , Galectin 3/genetics , Galectin 3/metabolism , Hepatocytes/metabolism , Liver/drug effects , Liver/immunology , Liver/metabolism , Liver/pathology , Lymphocyte Activation/immunology , Macrophages/metabolism , Male , Mice , Mice, Transgenic , Spleen/cytology , Spleen/immunology , Th1 Cells/drug effects , Th1 Cells/immunology , Th1 Cells/metabolism , Th2 Cells/drug effects , Th2 Cells/immunology , Th2 Cells/metabolism
9.
Proteomics Clin Appl ; 7(9-10): 648-56, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23775887

ABSTRACT

PURPOSE: Mac-2 binding protein (Mac-2 bp) is one of the major fucosylated glycoproteins, which we identified with glycol-proteomic analyses. We previously reported that fucosylated glycoproteins are secreted into bile, but scarcely secreted into sera in normal liver and hypothesized that the fucosylation-based sorting machinery would be disrupted in ballooning hepatocytes due to the loss of cellular polarity. In the present study, we investigated the availability of Mac-2 bp for differential diagnosis of nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver disease (NAFLD) as a biomarker. EXPERIMENTAL DESIGN: Serum Mac-2 bp levels were determined with our developed ELISA kit. Our cohort of 127 patients with NAFLD had liver biopsy to make a histological diagnosis of NASH and simple fatty liver. RESULTS: Mac-2 bp levels were significantly elevated in NASH patients compared with non-NASH (simple steatosis) patients (2.132 ± 1.237 vs. 1.103 ± 0.500 µg/mL, p < 0.01). The area under the receiver-operating characteristic curve for predicting NASH by Mac-2 bp was 0.816. Moreover, multivariate logistic regression analyses showed Mac-2 bp levels could predict the fibrosis stage and the presence of ballooning hepatocytes in NAFLD patients. CONCLUSIONS AND CLINICAL RELEVANCE: These results support the potential usefulness of measuring Mac-2 bp levels in clinical practice as a biomarker for NASH.


Subject(s)
Antigens, Neoplasm/blood , Membrane Glycoproteins/blood , Non-alcoholic Fatty Liver Disease/blood , Non-alcoholic Fatty Liver Disease/diagnosis , Antigens, Neoplasm/metabolism , Biomarkers/blood , Biomarkers/metabolism , Case-Control Studies , Cell Line , Female , Fucose/metabolism , Humans , Male , Membrane Glycoproteins/metabolism , Middle Aged , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL
...